Simtuzumab ( Investigational drug (no approved brand names - development discontinued) )

Immunotherapy

med_ema_not_submitted

med_spain_not_available 1 Clinical Trials

Description

Simtuzumab is an investigational immunotherapy drug that was studied in clinical trials for colorectal cancer. It was specifically investigated for people with metastatic colorectal cancer that had KRAS mutations and had already progressed after initial treatment. In the main trial (NCT01479465), simtuzumab was given in combination with a standard chemotherapy regimen called FOLFIRI (fluorouracil, leucovorin, and irinotecan). The goal of the trial was to see if adding simtuzumab to FOLFIRI would improve progression-free survival (the time during which the cancer does not grow or spread) compared to FOLFIRI alone. Simtuzumab works by targeting a specific protein on cancer cells, potentially helping the immune system recognize and attack the tumor. Development of simtuzumab has been discontinued.

Mechanism of Action

Simtuzumab is designed to target a specific protein found on the surface of certain cancer cells. By binding to this protein, it may help the body's immune system identify and destroy the cancer cells. The specific protein targeted by simtuzumab is being characterized in clinical trials.

Side Effects

As an investigational drug The full range of side effects for simtuzumab is still being evaluated. In the clinical trial (NCT01479465) combining simtuzumab with FOLFIRI Side effects were likely related to both the drug and the chemotherapy regimen. Common side effects of FOLFIRI include nausea Vomiting Diarrhea Fatigue And low blood counts. Specific side effects related to simtuzumab itself are still being evaluated in ongoing trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT01479465 med_phase_prefix2

Archived

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

United States, France, Germany, Italy, Poland, Russia, Spain

Quick Info

Brand Name	Investigational drug (no approved brand names - development discontinued)
Category	Immunotherapy
Estado EMA	med_ema_not_submitted
Acceso España	med_spain_not_available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Simtuzumab (** Investigational drug (no approved brand names - development discontinued) **)